doi: 10.1016/j.imbio.2009.12.005 39 KumarRNChambersWAPertweeRG
FOXO4-DRI enters senescent cells and competitively binds to p53 through its modified peptide sequence, displacing endogenous FOXO4 and freeing p53 to activate cell death pathways including BAX and PUMA
Drugs: OXYGEN (by face mask or nasal cannula) BRONCHODILATORS: Short Acting Beta2 Agonists ( SABAs ): albuterol, levalbuterol Long Acting Beta2 Agonists ( LABAs ): formoterol , salmeterol Antimuscarinics: ipratropium , tiotropium 1) ANTIINFLAMMATORY DRUGS: Corticosteroids ( ICS ): beclomethasone, budesonide, fluticasone, prednisone, prednisolone SMART / COMBINED ICS+FORMOTEROL (Rescue & Control): budesonide + formoterol (Symbicort ) ICS + LABA momentasone + formoterol (Dulera ) ICS + LABA COMBINED ICS + ALBUTEROL (Rescue): budeosnide + albuterol (Airsupra ) ICS + SABA LEUKOTRIENE PATHWAY INHIBITORS: Receptor Antagonists: montelukast , zafirlukast 5-lipoxygentase inhibitor: zileuton ANTI-IgE THERAPY (Allergic asthma) TARGETED BIOLOGIC ANTI-IL THERAPIES (Eosinophilic Asthma / Refractory Asthma): Misc IL-4, IL-5, IL-13 Specific Monoclonal antibodies RARELY USED: cromolyn sodium (low-efficacy degranulation inhibitor) theophylline (low efficacy bronchodilator, life-threatening toxicity, narrow TI) terbutaline (oral & s.c
References 1 AgiusF.Gonzlez-LamotheR.CaballeroJ
